Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Last updated: 9 October 2026

Clear filter
681 clinical trials found
Clinical trials

GMO-RP2-202

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma (NCT06581406)

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy. This study investigates the Genetically Modified Organism (GMO) RP2.
Currently recruiting

GNIA-001

An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy (NCT05947656)

Currently recruiting

GO42144

A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION (NCT04449874)

Currently recruiting

GO42552

AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLUS DARATUMUMAB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (CAMMA 1) (NCT04910568)

Currently recruiting

GO43073

A Phase 1b, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (NCT05243342)

Currently recruiting

GO43979

AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE COMBINATION OF CEVOSTAMAB AND ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (GO43979) (NCT05927571)

Currently recruiting

GO43980

A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (GO43980) (NCT05646836)

Currently recruiting

GOLDEN GATE

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study) (NCT04994717)

Currently recruiting

GOlDiLOX

[NHL37] An open-label, single-arm, phase 2 trial of GlOfitamab anD pIrtobrutinib [LOXo-305] in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor – GOlDiLOX (NCT05833763)

Currently recruiting

GS-US-536-5939

A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)

Currently recruiting

GS-US-548-5916

GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)

No longer recruiting

GS-US-587-6156

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (NCT05330429)

No longer recruiting

Guanethidine for PH-HFpEF

Guanethidine for Pulmonary Hypertension with Heart Failure with a Preserved Ejection Fraction [PH-HFpEF] (ACTRN12625000817448)

This study will help the researchers understand if guanethidine, a drug used to treat hypertension, is safe and effective in patients with PH-HFpEF.
Currently recruiting

H-MEET

Home-based Minimal Equipment Exercise Training (H-MEET) delivered using remote supervision: A randomised controlled feasibility study (ACTRN12625000550404)

Currently recruiting

HABOR

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (HABOR) (NCT04910685)

Currently recruiting

HALEO

HALEO - A phase 3, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2002 in participants with hereditary angioedema [HAE] (NCT06634420)

Currently recruiting

HALFMOON

Evaluation of safety and performance of the Half Moon Transcatheter Mitral Valve Repair (TMVr) System in High Risk Patients with Severe Symptomatic Mitral Regurgitation. (ACTRN04343313)

No longer recruiting

HB-1 PTSD

Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study (NCT07499440)

A phase 2 Clinical Trial investigating a combination of antihypertensive medications to improve symptoms of PTSD
Currently recruiting

HB-PD-002

Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (NCT05071430)

Currently recruiting

Hearts and Minds

Hearts and Minds: A 3-arm Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Metformin and Atorvastatin for the Treatment of Depression and Medical Comorbidity (ACTRN12623000611628)

Currently recruiting
14 15 16 17 18